TY - JOUR
T1 - Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis
AU - Ito, Hiromu
AU - Murata, Koichi
AU - Sobue, Yasumori
AU - Kojima, Toshihisa
AU - Nishida, Keiichiro
AU - Matsushita, Isao
AU - Kawahito, Yutaka
AU - Kojima, Masayo
AU - Hirata, Shintaro
AU - Kaneko, Yuko
AU - Kishimoto, Mitsumasa
AU - Kohno, Masataka
AU - Mori, Masaaki
AU - Morinobu, Akio
AU - Murashima, Atsuko
AU - Seto, Yohei
AU - Sugihara, Takahiko
AU - Tanaka, Eiichi
AU - Nakayama, Takeo
AU - Harigai, Masayoshi
N1 - Funding Information:
We would like to appreciate Ms. Mieko Hasegawa, Chair of the Japan Rheumatism Friendship Association, for her valuable suggestions from the patients’ point of view. We also would like to thank Prof. Emeritus Hisashi Yamanaka for his tremendous support and mentorship for this work. This work was supported by Health and Labor Sciences Research Grants for Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare (Grant No. H30-Meneki-Shitei-002).
Funding Information:
HI and KM belong to the department that is financially supported by Nagahama city, Toyooka city, and five pharmaceutical companies (Mitsubishi-Tanabe, Chugai, UCB Japan, AYUMI, and Asahi-Kasei). HI has received research grants from BMS, AbbVie, Eisai, Taisyo, and Mochida. MM belongs to the department that is financially supported by Chugai, UCB Japan, CSL Behring, Abbvie Japan, Japan Blood Products Organization, AYUMI, Nippon Kayaku, and Asahi-Kasei and has received lecture fee from MSD and consulting fee from Daiichi Sankyo and Taisho. YK has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. YK has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. AM has received speaking fees and/or research grants from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Pfizer Inc., UCB Japan, AbbVie G.K., Asahi Kasei Pharma and Chugai Pharmaceutical Co. Ltd. TS has received research grants and/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. Tokyo Medical and Dental University (TMDU) received unrestricted research grants for Department of Lifetime Clinical Immunology from Ayumi Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, and UCB Japan Co. Ltd. MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer-ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma. The other authors declare no conflicts of interest on this study. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.
Publisher Copyright:
© 2021 Japan College of Rheumatology.
PY - 2021
Y1 - 2021
N2 - Objectives: To examine the risk factors of surgical site infection (SSI), delayed wound healing, and death after orthopedic surgery in patients with rheumatoid arthritis (RA). Methods: We identified articles indexed in the Cochrane Library, PubMed, and Japan Centra Revuo Medicina Web published from 2013 to 2019 and other articles. Articles fulfilling the predefined inclusion criteria were reviewed systematically and their quality was appraised according to the Grading of Recommendations Assessment, Development, and Evaluation system with some modifications. Results: After inclusion and exclusion by full-text review, 29 articles were analyzed. Use of biological disease modifying antirheumatic drugs was a risk factor of SSI (risk ratio 1.66, 95% confidence interval 1.25–2.19), but not of delayed wound healing. RA itself was a risk factor of SSI, and oral glucocorticoid use was a risk factor of SSI in three of the four studies analyzed and of postoperative death. Age, male sex, comorbidities such as diabetes mellitus and chronic obstructive pulmonary disease, surgical factors such as foot/ankle and spine surgery and longer operative time were risk factors of those postoperative complications. Conclusion: Patients with those factors should be dealt with appropriate cautions to strike a risk–benefit balance of orthopedic surgeries.
AB - Objectives: To examine the risk factors of surgical site infection (SSI), delayed wound healing, and death after orthopedic surgery in patients with rheumatoid arthritis (RA). Methods: We identified articles indexed in the Cochrane Library, PubMed, and Japan Centra Revuo Medicina Web published from 2013 to 2019 and other articles. Articles fulfilling the predefined inclusion criteria were reviewed systematically and their quality was appraised according to the Grading of Recommendations Assessment, Development, and Evaluation system with some modifications. Results: After inclusion and exclusion by full-text review, 29 articles were analyzed. Use of biological disease modifying antirheumatic drugs was a risk factor of SSI (risk ratio 1.66, 95% confidence interval 1.25–2.19), but not of delayed wound healing. RA itself was a risk factor of SSI, and oral glucocorticoid use was a risk factor of SSI in three of the four studies analyzed and of postoperative death. Age, male sex, comorbidities such as diabetes mellitus and chronic obstructive pulmonary disease, surgical factors such as foot/ankle and spine surgery and longer operative time were risk factors of those postoperative complications. Conclusion: Patients with those factors should be dealt with appropriate cautions to strike a risk–benefit balance of orthopedic surgeries.
KW - Rheumatoid arthritis; systematic review; postoperative complication; biological agent; surgical site infection
UR - http://www.scopus.com/inward/record.url?scp=85113947777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113947777&partnerID=8YFLogxK
U2 - 10.1080/14397595.2021.1913824
DO - 10.1080/14397595.2021.1913824
M3 - Article
C2 - 33855932
AN - SCOPUS:85113947777
SN - 1439-7595
JO - Modern Rheumatology
JF - Modern Rheumatology
ER -